CDH1 and cancer: Therefore, FAKY925 cooperates with Src disrupting E-cadherin-based intercellular cadherin junctions and promoting E-cadherin internalization during cancer progression [44–47], and hence, facilitating EMT and enhancing tumor cell motility and invasiveness.